RCKT Earnings & Financial Statements
Rocket Pharmaceuticals, Inc.
$2.29
+$0.08(+3.39%)
37
Overall
60
Value
36
Tech
15
Quality
Market Cap
$242.60M
Volume
195.28K
52W Range
$2.42 - $5.45
Target Price
$8.21
RCKT earnings and financial statements: Rocket Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RCKT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cost of revenue | - | - | $1.40M | $1.20M | $1.10M |
| Operating income | -$231.75M | -$273.20M | -$259.66M | -$224.34M | -$167.25M |
| EBITDA | -$212.36M | -$249.64M | -$238.78M | -$216.02M | -$157.81M |
| Net income | -$223.12M | -$258.75M | -$245.59M | -$221.86M | -$169.07M |
| EPS (diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $330.45M | $527.70M | $566.34M | $551.81M | $497.02M |
| Total liabilities | $53.23M | $64.47M | $73.77M | $62.12M | $42.30M |
| Shareholders’ equity | $277.22M | $463.23M | $492.57M | $489.69M | $454.72M |
| Cash and equivalents | $77.56M | $163.63M | $55.90M | $140.52M | $232.69M |
| Long-term debt | $21.96M | $22.64M | $22.33M | $20.36M | $20.05M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$190.01M | -$209.72M | -$194.92M | -$178.14M | -$121.16M |
| Capital expenditure | -$440.0K | -$5.86M | -$16.47M | -$8.62M | -$7.71M |
| Free cash flow | -$190.45M | -$215.59M | -$211.39M | -$186.76M | -$128.88M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RCKT | $2.29 | +3.4% | 195.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Rocket Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW